Intensive insulin therapy has significant anti-inflammatory effects during critical illness [63]; hence, it should not be discontinued in patients with DM who develop COVID-19 and should be considered for patients receiving oral antidiabetic drugs who have a poor glycemic profile. Here, INS is linked to COVID-19.